Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Chinese Participants With Overweight or Obesity
NCT06820476Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of amycretin in Overweight and obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Feb 2025; status: completed.
02
Drugs
amycretin
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06820476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820476.